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ABSTRACT
Wnt/β-catenin signaling is responsible for the generation of cancer stem cells 
(CSCs) in many human tumors, including nasopharyngeal carcinoma (NPC). Recent 
studies demonstrate that Wnt or PORCN inhibitor, Wnt-C59, inhibits tumor growth 
in MMTV-WNT1 transgenic mice. The effect of Wnt-C59 in human tumors is not clear. 
In this study, the NPC cell lines investigated manifest heterogeneous responses 
to Wnt-C59 treatment. Wnt-C59 decreased tumor growth of SUNE1 cells in mice 
immediately following the administration of Wnt-C59. Mice injected with HNE1 cells 
did not develop visible tumors after the treatment of Wnt-C59, while control mice 
developed 100% tumors. Wnt-C59 inhibited stemness properties of NPC cells in a 
dosage-dependent manner by arresting sphere formation in both HNE1 and SUNE1 
cells. Thus, Wnt-C59 has the potential to eradicate CSCs in human tumors. Active 
β-catenin and Axin2 proteins were strongly expressed in stromal cells surrounding 
growing tumors, confirming the importance of Wnt signaling activities in the 
microenvironment being driving forces for cell growth. These novel findings confirm 
the ability of Wnt-C59 to suppress Wnt-driven undifferentiated cell growth in NPC. 
Both anti-Wnt signaling and anti-CSC approaches are feasible strategies in cancer 
therapy.
INTRODUCTION 
The central concept of cancer stem cells (CSCs) is 
that the bulk of tumor cells contain a tiny cell population 
having self-renewal ability to sustain the long-term tumor 
proliferation against chemotherapy. Efforts to control the 
growth of these unique tumor cells are a major effort in 
current translational and clinical cancer research [1, 2]. 
A growing number of studies indicate that inappropriate 
activation of Wnt/β-catenin signaling correlates with the 
generation of CSCs in many tumor types [3-8]. Therefore, 
targeting of this pathway may provide the means to safely 
eradicate CSCs and identify novel molecular targets for 
cancer therapy [9, 10].
Activation of Wnt/β-catenin signaling associated 
with self-renewal is context-dependent in many human 
tumors [11-13]. Dosage levels of Wnt signaling and genetic 
background of tissues play critical roles in regulating 
self-renewal tumor cell networks [3, 14, 15]. Lack of 
knowledge underlying signal transduction mechanisms 
clearly impedes the exploration of effective therapeutic 
targets for this pathway [9, 10, 16]. A few promising Wnt 
targeting molecules, such as ICG001 [17], XAV939 [18], 
and Wnt-C59 [19], have been recently reported. Porcupine 
(PORCN) is a membrane bound O-acyltransferase 
(MBOAT) family that is essential for Wnt palmitoylation, 
secretion, and other biological activities, indicating that 
PORCN activity is a key modulator of Wnt signaling [16, 
20]. Wnt-C59 is a strong and specific PORCN inhibitor. 
This small molecule is similar to other Wnt inhibitors, 
IWP family and LGK974, that inactivate PORCN function 
by directly inhibiting the PORCN active site or affecting 
Oncotarget14429www.impactjournals.com/oncotarget
regulators such as Axin2 [7, 16, 20, 21]. A model of fine-
tuning of the Wnt pathway by Wnt-C59 was proposed 
in which either β-catenin-mediated or its downstream 
components-mediated activities are arrested by PORCN 
inhibitors [22]. Several recent studies provide evidence 
showing that PORCN inhibitors, including Wnt-C59 and 
LGK974, inhibit or delay tumor growth in mouse models. 
These experiments were performed in MMTV-WNT1 
transgenic mice and findings indicate that mammalian 
physiological Wnt signaling is sensitive to PORCN 
expression levels. Small changes in PORCN activity 
can induce significant inhibitory effects in rodent tumor 
models. Notably, Wnt-C59 and LGK974 are safe agents 
as verified in these animal studies and the latter is now in 
the phase I clinical trials [20, 23]. 
Recent findings reveal the vital role of Wnt signaling 
in both epithelial and stromal cells; inhibitory effects of 
Wnt-C59 mimick the PORCN knockout mouse to block 
proliferation of intestinal stem cells at physiological 
conditions [24]. However, whether targeting the Wnt 
pathway can be achieved to eradicate human CSCs by 
affecting the tumor microenvironment is largely unknown. 
Using reduced expression of Axin2 mRNA as a reporter, 
Liu et al screened many human tumor cells, including 
brain, lung, and colon cancers and lymphoma/leukemia, 
and only detected a few (31%, 31/96 cases) head and neck 
squamous cell carcinoma (HNSCC) cell lines that were 
sensitive to the PORCN inhibitor treatment. One of these 
HNSCC cell lines, HN30, delays tumor growth within 
a 15-day period in vivo, following the administration 
of LGK974 [20]. Only a fraction of human tumors are 
sensitive to PORCN inhibitors, although aberrant Wnt 
signaling is widely reported in many human tumors [25]. 
We already know that precise regulation of PORCN 
activity is required for physiologically relevant expression 
levels of Wnt signaling, which might fine-tune network 
activities over a large dynamic range [19]. Therefore, 
many human tumor cells may not have responded to 
PORCN treatment because of the inappropriate or 
overexpressed levels of Wnt pathway activities or the 
involvement of other interacting pathways induced by 
aberrant Wnt signalling and accumulated mutations in 
these cells. However, such tumor models with dominant 
activation of Wnt signalling are limited for current studies. 
Our early studies show that self-renewal networks 
in nasopharyngeal carcinoma (NPC) stem-like cells are 
precisely regulated by dominant physiological levels 
of Wnt/β-catenin signaling [3]. The exogenous Wnt 
signaling in these cells, interacting with p53, RB1, TGF-β, 
epithelial-mesenchymal transition and other pathways, can 
induce extensive signaling cascades and regulate LIFR- 
and IL6ST-mediated cell self-renewal networks. More 
importantly, inhibition of Wnt signaling in these stem-like 
cells could effectively suppress cell growth and sphere 
formation. Given the key roles of Wnt/β-catenin signaling 
in NPC [26], it is an attractive therapeutic approach to 
test PORCN inhibitor in this unique human cancer. Using 
several NPC cell lines, we now demonstrate that a PORCN 
inhibitor is able to inhibit Wnt signaling activities, arrest 
stemness properties, and suppress tumor cell growth in 
animal assays. Although these results vary depending on 
the context of NPC cells, these novel findings demonstrate 
that inhibition of Wnt signaling is a promising therapeutic 
approach in certain human tumors. 
RESULTS 
Wnt-C59-sensitive cell lines in mice have stemness 
properties in cell culture
To determine whether NPC cells are sensitive 
to Wnt-C59 treatment, as reported in other head and 
neck tumors, we established a 3-dimensional (3D) cell 
culture system [27]. Plating cell densities influenced 
3D sphere-formation abilities because most cells grew 
as a monolayer and only a small population of cells 
was capable of sphere formation. Cells growing as a 
monolayer surrounding the spheres might change to 3D 
growth, reflecting a NPC stemness property influenced 
by the local microenvironment. After 30 days culture, 
experiments were terminated and examined for sphere 
formation. C666-1 cells grow quickly, but most cells form 
a colony-like morphology and do not show obvious 3D 
cell growth. The sphere-formation ability was weak for 
both CNE1 and HK1 cells compared to HNE1 and SUNE1 
cells that exhibited fast cell growth abilities and formed 
relatively large spheres (Figures 1A and 1B). 
Previous studies indicated that Wnt-C59 did not 
significantly inhibit in vitro proliferation in 46 cancer cell 
lines at concentrations that might inhibit PORCN. The 
IC50 was greater than 50 µM in 87% of tested cell lines 
[23]. To investigate anti-stemness activities induced by 
Wnt-C59 in NPC cells, we investigated possible growth 
influences of this small molecule in a NPC cell line 
panel. As shown in Figure 1C, SUNE1 cells exhibited a 
strong tolerance to this agent, as reported in many other 
human cancer cell lines. Both CNE1 and HNE1 cells 
showed reduced growth abilities in the higher Wnt-C59 
concentration (20 µM), while HK1 cells were sensitive to 
all concentrations (5 µM, 10 µM, and 20 µM) of Wnt-C59 
treatments. 
Both SUNE1 and HNE1 cells showed a greater 
ability to form spheres (Figures 1A and 1B). Their IC50 
for Wnt-C59 treatment at 48 hours is greater than 60 µM. 
Additionally, these two cell lines have obviously different 
in vivo cell growth dynamics, providing good animal 
models to determine biological effects of Wnt-C59 in NPC 
cells. HNE1 cells display less aggressive tumor growth 
in mice. While the majority of injected HNE1 cells (1 x 
107) die and injected cell nodules shrink for about 2 or 3 
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weeks post-injection, a fraction of the population survived 
and subsequently expanded to form progressively growing 
tumors after a period of latency, as seen in the control 
group mice (Figure 2A and 2B). In the 41-day testing 
period, the first and last growing tumors of the controls 
appeared on days 20 and 38, respectively, reflecting highly 
heterogeneous tumor behaviors. Shortly after the latency 
period, visible tumors were observed in all injected sites 
(7/7). In contrast, all injected tumor nodules shrank and 
disappeared following the administration of Wnt-C59 in 
3 weeks and no visible and progressively growing tumors 
were detected in any injected sites (0/8) in 41 days, as 
shown in Figures 2A and 2B. Histological examination 
confirmed that all growing nodules in the control group 
contained tumor cells. Figure 2C shows a representative 
hematoxylin and eosin (H&E)-stained section of the 
smallest tumor finally appearing in mice. Therefore, the 
complete suppression of HNE1 cells in vivo confirms 
that the growth of the NPC subcutaneous tumor can be 
inhibited by Wnt-C59. 
Figure 1: Stemness activity and Wnt-C59 treatment in NPC cells. A. Phase-contrast sphere images from NPC cells. C666-1, 
CNE1, and HK1 cells generate relatively small spheres, but both HNE1 and SUNE1 cells can form large spheres (usually larger than 200 
µm in diameter). B. Areas of average 3D growth are summarized. C666-1 cells grow more like colonies, but are counted as 3D growth. C. 
Cell proliferation influenced by concentrations of Wnt-C59 treatment. Wnt-C59 has a clear inhibitory effect on the growth of HK1 cells. 
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In contrast to HNE1, SUNE1 is a fast-growing 
cancer cell line. We tested tumor inhibitory effects of 
Wnt-C59 in nude mice following injection of SUNE1 
cells. Figure 2D shows that Wnt-C59 inhibits SUNE1 cell 
growth immediately after administration of this agent for 
the 13-day period of tumor growth in mice. Compared to 
tumor sizes of control groups, average inhibited tumor 
sizes in Wnt-C59-treated animals were significantly 
smaller (p < 0.001). Comparison of tumor weights from 
both control and experimental groups is shown in Figure 
Figure 2: Wnt-C59 suppresses tumor growth in animals. A. Growth curves show that Wnt-C59 completely suppresses the growth 
of Wnt-driven HNE1 cell in the animal assay. Arrowheads (on days 1 and 3 after cell injection) indicate the administration of Wnt-C59 
by tail vein injection and drinking water, respectively. Tumor volume, mean ± SEM. No tumor growth is detected in Wnt-C59 treated 
animals, and the numbers in parentheses indicate the tumor incidence. B. Images of representative mice with or without tumors (top) and 
excised tumors from control group (bottom). Red arrowheads indicate growing tumors (top) and the smallest/longest latency period tumor 
(bottom) appearing on day 38 following injection of HNE1 cells in control mice. C. H&E staining shows the last tumor appearing on day 
38 following injection of HNE1 cells in control mice. D. Growth curves show inhibitory effects of Wnt-C59 on SUNE1 cell growth in 
nude mice. Arrowheads (on days 1 and 3 after cell injection) indicate the administration of Wnt-C59 by tail vein injection and drinking, 
water, respectively. Tumor volume, mean ± SEM. E. Comparison of tumor weights in control and Wnt-C59-treated mice shows Wnt-C59 
treatment clearly reduce tumor growth (p < 0.001). 
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2E, revealing that average tumor weights of the Wnt-C59-
treated groups were significantly lower than for control 
mice (p < 0.001). 
Wnt-C59 suppresses in vivo tumor growth and 
high Wnt-C59 concentrations are also effective in 
in vitro assays
A low concentration (1 µM) of Wnt-C59 treatment 
suppresses SUNE1 cells and 3D growth was clearly 
inhibited compared to control untreated cells (Figure 3A). 
The inhibitory effects of Wnt-C59 were dosage-dependent 
in these NPC cells; both 5 µM and 20 µM Wnt-C59 
treatments can arrest sphere formation in both HNE1 and 
SUNE1 cell lines, but not CNE1 cells. However, cells 
showing a monolayer growth with Wnt-C59 treatments 
were continuously expanding and both 3D inhibition and 
monolayer growth were consistent, as observed from 
weeks 1 to 3 (Figure 3B). 
After a three-week treatment, we withdrew 
Wnt-C59 and continued to culture cells for 10 to 20 days 
more under control cell culture conditions. No obvious 3D 
Figure 3: Wnt-C59 arrests 3D growth in NPC cells. A. Phase-contrast images show that the Wnt-C59 (1 µM) clearly inhibits 
sphere formation in SUNE1 cells, compared with control cells. 4X, microscopy using the 4X objective, other images used 10X objective. 
* The same image is used for the HNE1 control cells on week 3 of Wnt-C59 treatment. B. The higher concentration of Wnt-C59 (5 µM) 
strongly inhibits sphere formation and growth in both HNE1 and SUNE1 cells, but not in CNE1 cells. Bar, 100 µm. C. Phase-contrast 
images of growing cells following the removal of Wnt-C59 treatment (5 µM). Only SUNE1 cells resume sphere growth recorded on 
days 10 and 20 and no sphere is detected in HNE1 cells. Bar, 100 µm. D. ICG001 and XAV939 do not cause obvious inhibition of sphere 
formation in both HNE1 and SUNE1 cells compared to their controls. Images are captured at the end of the first week of the treatments 
with these two agents. Bar, 100 µm.
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growth resumed or was detected in HNE1 cells, although 
cell densities and incubation periods were sufficient 
to generate 3D growth for untreated cells. However, 
monolayer-growing SUNE1 cells gradually formed huge 
spheres in 20 days under untreated culture conditions 
(Figure 3C). These findings indicated that inhibitory 
effects of Wnt-C59 on stemness were irreversible as seen 
in HNE1. The HNE1 cells with stemness properties in the 
whole cell populations could be safely eradicated by the 
Wnt inhibitor. 
To verify the different effects of the Wnt inhibitors 
in our established sphere-formation system, we evaluated 
two other non-PORCN inhibitors, ICG001 and XAV939, 
as previously described. As expected, no obvious anti-
stemness effects were observed by these two agents after 
three weeks of culture of HNE1 and SUNE1 cells (Figure 
3D) even at higher concentrations of agents. Compared to 
control cells, no obvious growth inhibition was induced, 
confirming that these two Wnt inhibitors have different 
regulatory effects in the tumor cells. 
Wnt-C59 inhibits the Wnt pathway in vivo
Wnt signaling in the stroma plays a vital role in the 
stem cell niche, as reported recently [24]. Therefore, we 
examined protein expression of active β-catenin and Axin2 
in tumor tissues. These two proteins clearly accumulated 
Figure 4: Wnt/β-catenin pathway is activated in the niche of growing tumors. A. IHC staining shows that strong expression 
of both active β-catenin and Axin2 is detected in stromal cells around cancer nests derived from both control and Wnt-C59-treated mice 
with injected SUNE1 cells. The representative images of β-catenin expression under both higher and lower power objectives are presented, 
and a negative control without using primary antibodies is also included. B. Wnt signaling is up-regulated in tumor tissues obtained from 
control mouse injected with HNE1 cells and IHC staining shows that extensive expression of Axin2 is detected in stromal cells around 
cancer nests (top). The β-catenin is also expressed in stromal tissues of tumor (bottom). C. and D. Wnt-C59 has systemic effects in mice 
injected with HNE1 cells. Both active β-catenin and Axin2 expression are down-regulated in liver and kidney in Wnt-C59-treated mice, 
compared with those from control mice.
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in stromal cells around cancer nests, especially in the 
fast-growing region of the tumor tissues. No obvious 
difference of expression of these two proteins was detected 
between control and Wnt-C59-treated mice with injected 
SUNE1 cells, indicating that the tumor microenvironment 
in SUNE1 (Figure 4A) and HNE1 cells (Figure 4B) had 
favorable and up-regulated Wnt pathway activities. The 
Wnt-C59 had limited influence on these growing tumors 
in treated mice with injected SUNE1 cells. 
Importantly, expression of active β-catenin and 
Axin2 in liver (Figure 4C) and kidney (Figure 4D) was 
clearly down-regulated in the Wnt-C59-treated HNE1 cell-
injected mice compared to control mice. These findings 
confirmed that the administration of Wnt-C59 generated a 
systemic influence on the Wnt pathway in treated animals 
within a 41-day assay period, which induced tumor 
suppression in tested mice. 
We recently reported that NPC HONE1 cells have 
very low endogenous activities of the Wnt pathway, 
especially expression of β-catenin [3]. Using this line 
as a control, we compared Wnt activities in HNE1 and 
SUNE1 cells. Western blotting confirmed that both HNE1 
and SUNE1 cells expressed β-catenin and Axin2 proteins, 
which are key mediators of the Wnt pathway (Figure 5A). 
Notably, the active form of β-catenin was also detected in 
these two cell lines, reflecting that the activated Wnt/β-
catenin signaling status in both HNE1 and SUNE1 cells, 
compared to control HONE1 cells. 
Expression changes of β-catenin and Axin2, derived 
from Wnt-C59-treated and control spheres (DMSO) cells 
(Figure 3B), is seen in Figure 5B; expression of both 
genes was inhibited by Wnt-C59 (5 µM) in both HNE1 
and SUNE1 cells. 
To understand the influence of the Wnt pathway 
in tumor microenvironments, we examined SUNE1 
cell-derived mouse tumors with and without Wnt-C59 
treatment. Using parental SUNE1 cells as controls, the 
PCR assays showed the increased expression of β-catenin 
(Figure 5C) and Wnt10B (Figure 5D) in all tumor samples, 
including both control and Wnt-C59-treated mice. There is 
no obvious difference in the expression of β-catenin and 
Wnt10B between Wnt-C59-treated and control tumors, 
suggesting that Wnt pathway activities are similar in these 
tumors derived from SUNE1 cells. Because mouse tumors 
contain both SUNE1 and stromal cells, we compared 
β-catenin and Wnt10B expression to that of parental 
SUNE1 cells that had no stromal influences. As expected, 
mouse tumor tissues had higher Wnt activities compared 
to the in vitro cultured SUNE1 cell line. Additionally, 
Wnt10B expression, reported to be associated with 
Wnt-C59 treatment [7], increased with expression of 
β-catenin as expected. These results confirm the IHC 
staining findings detected in tumor tissues (Figures 4A 
and 4B), indicating that Wnt pathway activities, especially 
in the tumor microenvironment, stimulated SUNE1 cell 
tumor growth. 
DISCUSSION
A successful anticancer therapy should eliminate 
both the differentiated cancer cells and undifferentiated 
CSC populations. Although the CSC concept has been 
linked to resistance in cancer therapy for some tumor 
models, definitive evidence for functional suppression 
of tumor growth by manipulating both Wnt signaling 
and CSC activities is lacking. CSCs have the capacity 
to self-renew and this property is controlled by several 
developmental pathways, including Wnt signaling [3, 13, 
28]. Although there is lack of direct evidence showing 
the existence of CSCs in unmanipulated solid tumors 
[2], many studies revealed the CSCs may be present in 
tumors as a distinct small population driving relapse and 
metastasis by giving rise to new chemoresistant tumors 
[1]. A hypothetical issue is whether Wnt inhibitors can 
inhibit CSC activities, since tumor stemness properties 
have long been suggested to correlate with both Wnt 
activation and tumor proliferation [1, 10, 29]. Therefore, 
it is of interest to understand whether both cancer stemness 
and proliferation activities can be altered by regulating the 
Wnt signaling cascade in tumor cells. 
We focused on Wnt-mediated self-renewal signaling 
networks in NPC cells and detected that NPC stemness 
was precisely regulated by the physiological levels of 
Wnt/β-catenin signaling. We reported that multiple tumor 
suppressor pathways, including p53 and RB1, within NPC 
cells are important for maintaining a balanced environment 
for upregulation of β-catenin expression [3, 30]. 
Additionally, we recently found that BLU, one of the TSGs 
mapped to the chromosome 3p21.3 region, controlled the 
NPC microenvironment and angiogenesis [31]. Since 
β-catenin is extensively activated in NPC tissues [32] 
and cell lines (seen in this study) and CSC properties 
are strongly regulated by microenvironment [4], it is 
possible that these TSGs play critical roles in both Wnt- 
or stemness-mediated activities in NPC. Given the facts 
that inflammation and Epstein-Barr Virus infection are 
very common in NPC cells [33], these microenvironment 
changes may also influence Wnt signaling and expression 
of TSGs through epigenetic regulation. Further elucidation 
of these interacting mechanisms underlying the Wnt 
pathway in NPC may provide useful insight for the 
development of an effective therapeutic approach. 
One major stemness property in tumors is 3D 
sphere growth, which is widely used to explore dynamics, 
function, and regulation of stem cells for clonogenic 
growth potential [34]. To demonstrate the ability of Wnt 
inhibitors to suppress tumor stemness, we performed 
sphere inhibition assays in various NPC cells. In the 
ordinary culture conditions, these NPC cells usually grow 
as monolayers and do not form spheres. We now provide 
evidence confirming that cellular ability for 3D growth of 
some NPC cells is strongly correlated with the activation 
of the Wnt/β-catenin signaling and can be suppressed by 
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Figure 5: Wnt/β-catenin activities in HNE1 cells, SUNE1 cells, and tumor tissues. A. Western blotting reveals that Wnt/β-
catenin signaling activities in both SUNE1 and HNE1 cells are higher than that of control HONE1 cells, showing expression of active 
forms of β-catenin, and Axin2, a key regulator of the stability of β-catenin in the Wnt signaling in these two cell lines. B. qPCR analyses 
show the expression changes of Wnt pathway target genes following the treatment of Wnt-C59 in both HNE1 and SUNE1 cells. DMSO-
treated sphere cells are used as controls. C. and D. qPCR analyses reveal expression changes of β-catenin and Wnt10B in tumor samples 
derived from both control and Wnt-C59-treated mice, compared to those of the parental cell line SUNE1 cells. 
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the Wnt inhibitor, Wnt-C59. 
NPC, like other human tumors, harbors genetically 
distinct subclones, which influence cellular heterogeneity 
in tumor behaviors. Recent study demonstrated that 
the Wnt pathway was responsible for this hierarchical 
configuration in tumor cells [35]. Like another Wnt 
inhibitor, ICG001, inhibitory effects of Wnt-C59 on cell 
proliferation and sphere formation were context-dependent 
in breast cancer [7]. However, the PORCN inhibitory 
approach is only suitable for a limited number of tumor 
cell lines having aberrant Wnt activation, as described 
previously. Our current investigations demonstrate 
that the great diversity of cells impacts tumor behavior 
and is an important and unavoidable issue faced when 
molecular therapy approaches are explored, as seen in 
CNE1, SUNE1, HNE1, and other HNSCC cells [36]. 
The Wnt pathway activities differ in these cells and 
influence responses to Wnt-C59 treatment. Consequently, 
the CNE1 stemness activity was not obviously inhibited 
by the PORCN inhibitor, reflecting heterogeneity of 
NPC cells and suggesting that other pathways, such as 
EGFR and AKT, possibly contribute to CNE1 stemness 
[37]. Although the Wnt pathway strongly correlates 
with stemness properties in some NPC cells, two Wnt 
inhibitors, ICG001 and XAV939, did not show obvious 
inhibitory effects on stemness in treated cells. These 
results suggest differences in regulatory networks are 
controlled by the complicated Wnt signaling in human 
tumor cells [8, 9]. 
We chose both SUNE1 and HNE1 cell lines 
with distinct growth dynamics for animal studies. The 
hypothesis is if Wnt signaling was dominant in the control 
of cellular stemness and proliferation, it would be possible 
to demonstrate the inhibitory effects by Wnt-C59 in these 
cell lines. Wnt-C59 treatment obviously delayed the 
growth of SUNE1 cells immediately after administration 
of tested chemicals in animals, but expression of active 
β-catenin protein was detected in tumor stroma. The 
findings suggested that Wnt-C59 was not able to fully 
control the CSC microenvironment to favor SUNE1-
induced tumor growth in animals. It was also possible that 
some unknown negative feedback or redundant regulatory 
mechanisms finally dominated the signaling networks 
that caused restoration of Wnt activities and tumor cell 
proliferation in SUNE1 cells. 
To detect long-term effects of Wnt-C59 in animals, 
which have not been reported yet, we investigated tumor 
growth of HNE1 cells. These cells require a longer 
latency period to form growing tumors in mice, reflecting 
greater intra-tumoral heterogeneity in this cell line. In the 
control group, surviving tumor cells, presumably CSCs, 
expanded in the injection sites and formed progressively 
growing tumors very quickly after the latency period. In 
contrast, injected tumor cells died and did not form visible 
and progressively growing tumors after the treatment 
of Wnt-C59 in animals. It was not possible to directly 
show the presence of CSCs in injected HNE1 cells, but 
the sphere inhibition assay demonstrates that Wnt-C59 
could safely eliminate cells with stemness properties in 
an irreversible manner. Both in vitro and in vivo assays 
further confirm these findings and support the notion for 
the presence of CSCs in this cell line. 
Targeting CSCs to suppress tumor growth is a major 
focus in current cancer research [38]. The current findings 
demonstrate that Wnt-C59 can effectively suppress Wnt 
signaling and stemness properties of certain tumor cells. 
We provide functional evidence demonstrating the use of 
an anti-CSC agent for tumor growth control is a feasible 
approach in cancer therapy and may be broadly exploited 
in human tumors. 
MATERIALS AND METHODS
Cell lines and culture conditions
NPC CNE1, HK1, HNE1, HONE1, and SUNE1 
cells were maintained in Dulbecco’s modified eagle 
medium (DMEM) supplemented with 10% FBS. All 
these cell lines were obtained from the Hong Kong NPC 
AoE Cell Line Repository (Center for NPC Research at 
University of Hong Kong, Hong Kong) and have been 
authenticated by genotyping analysis. C666-1 cells were 
cultured in RPMI supplemented with 10% fetal bovine 
serum. Cells for sphere and sphere inhibition assays were 
cultured in DMEM/F-12 medium (Life Technologies, 
Grand Island, NY, USA) supplemented with 10 ng/ml 
epidermal growth factor (R&D Systems, Minneapolis, 
MN, USA), 10 ng/ml basic fibroblast growth factor (R&D 
Systems), and B-27 Supplement (Life Technologies). 
All tested cells for stemness were maintained in Nunc 
HydroCell 24 multidish (Themo Fisher Scientific, 
Roskilde, Denmark). 
Wnt inhibitors
Wnt-C59 was obtained from Cellagen Technology 
(San Diego, CA, USA) and was dissolved in DMSO 
making a 10 mM stock solution following the 
manufacturer’s manual. Concentrations of 1 µM, 5 µM, 
10 µM and 20 µM were used as working solutions in in 
vitro assays. ICG001 and XAV939 were obtained from 
R&D Systems and Cellagen Technology, respectively, 
and 10 mM stock solutions were prepared in DMSO. The 
concentrations of 5 µM and 10 µM of these two agents 
were used as working solutions for in vitro assays.
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Cell proliferation and sphere formation assays
Approximately, 1 x 104 cells were seeded in 
24-well plates, and Wnt-C59 (5 µM, 10 µM, and 20 
µM) was added the next day. Each group was tested in 
triplicate and control groups with addition of DMSO 
were also established. Cell confluence was determined 
by microscopy at 24, 48, 72, and 96 hours after seeding 
of cells. The IC50 of Wnt-C59 was determined by MTT 
(3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium 
bromide) assay, using 96-well dishes. Next day, various 
concentrations of Wnt-C59 were added, and cellular 
viabilities were measured by a spectrophotometer at both 
24 and 48 hours.
For sphere formation, approximately one hundred 
cells were seeded onto the Low Cell Bind Surface 24-
well Nunc dish. Each group was done in triplicate and 
each well had 2 ml medium. Media were changed twice 
a week, and only half of the media was changed each 
time. Approximately, 1 x 103 cells were seeded for each 
well in the sphere inhibition assay. At 1 to 5 days after 
plating, all tested cells formed small spheres. Five days 
later, Wnt-C59 (1 µM, 5 µM, and 20 µM) was added into 
experimental groups. Abilities for cell growth and sphere 
images were compared and recorded at the end of the 
first, second, and third weeks after addition of Wnt-C59, 
or DMSO in control groups. The sphere growths were 
observed and recorded daily under microscopy, and the 
area of spheres was analyzed using Metamorph (Molecular 
Devices, Sunnyvale, CA, USA) and recorded as average 
area (µm2).
Western blotting
Western blotting was performed as previously 
described (3). The antibodies used in this assay are 
β-catenin (catalog # 9587, Cell Signaling,), Anti-Active 
β-catenin (catalog # 05-665, Millipore), and Axin2 
(catalog # 2151, Cell Signaling). The α-tubulin (catalog # 
CP06, Calbiochem) was used as a loading control for all 
experiments.
qPCR analyses
RNAs from tumor samples were extracted using the 
TRIzol reagent (Invitrogen, Carlsbad, CA, USA). Human 
GAPDH, primers GAAGGTGAAGGTCGGAGTC 
(forward) and GAAGATGGTGATGGGATTTC 
(reverse), was used as an internal control for all 
PCR reactions. The primers for qPCR are β-catenin: 
GGCTTGGAATGAGACTGCTGAT (forward) and 
CTGGCCATATCCACCAGAGTG (reverse); Axin2: 
CGCAGCAGTTTGGCGGCAGCA (forward) and 
AGGGTCCTGGGTGAACAGGTGGG (reverse); and 
Wnt10B: TGGGATGTGTAGCCTTCTCC (forward) and 
CCCAGCCAAAAGGAGTATGA (reverse). For qPCR 
analysis, triplicate PCR reactions were performed using 
the LightCycler 480 Real-Time PCR Instrument (Roche 
Diagnositics GmbH, Mannheim, Germany). 
Animal assay
The in vivo animal assays were performed as 
previously reported [39, 40]. A total of 1 x 107 cells in 
200 μl DMEM were injected into 4-8 week old nude mice 
subcutaneously. Next day, mice were randomly divided 
into two groups, experimental and control, and were 
given Wnt-C59 via vein injection. Based on previous 
reports [22-24], Wnt-C59 was dissolved in 30% propylene 
glycol for intravenous tail vein administration (2.5 mg/
kg). After 48 hours, Wnt-C59 was added into drinking 
water (5 mg/kg/day) for experimental groups. Fresh 
water with Wnt-C59 was changed every 48 hours in dark 
bottles avoiding light; water consumption was recorded 
and calculated. Mice in control groups were treated with 
injection of 30% propylene glycol and given fresh water 
containing DMSO. Tumor sizes were measured three 
times a week until the last day of the experiment. Injected 
tumor cell nodule growth or shrinkage was recorded and 
only progressively growing tumors, confirmed by both 
gross and histology examinations, were counted. Tumor 
incidence was determined based on tumor numbers on the 
last day of experiment and termination day of assay was 
decided depending on possible appearance of ulcers on 
the surface of fast-growing tumors in control animals. All 
animal experiments were approved by the Government 
of Hong Kong Special Administrative Region and the 
University of Hong Kong.
Histology and immunohistochemical staining
Mouse organs and tumor tissues were excised from 
mice, formalin-fixed, paraffin-embedded, and stained 
with H&E and IHC, as previously described (31). Primary 
antibodies of anti-Active β-catenin and Axin2 (Catalog # 
MABN259, Millipore) were used. The counterstain with 
hematoxylin was performed before mounting. The slides 
were scanned by ImageScope v11 software (Aperio, Vista, 
CA, USA). 
Statistical analysis
Differences between two groups were scored for 
statistical significances, using Student’s t-test or Chi-
square test.
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